Arexvy Now Available for Adults Aged 18–49 with Certain Health Conditions
The U.S. Food and Drug Administration has granted approval to expand GSK’s Arexvy respiratory syncytial virus (RSV) vaccine to a younger population, adults aged 18 to 49 years who face increased risk for severe RSV disease. According to PharmaBiz.com, this represents an important step forward in protecting a broader segment of the adult population from a virus that claims hundreds of thousands of healthcare visits annually.
Understanding the Expansion
Previously, Arexvy was approved in the United States only for adults aged 60 and older, and those aged 50–59 with specific risk factors. The new approval now makes the vaccine available to younger adults—those between 18 and 49, who have underlying health conditions that increase their vulnerability to severe RSV complications. The vaccine is not recommended for pregnant individuals.
Why This Matters
RSV, a common contagious virus that affects the lungs and breathing passages, impacts an estimated 64 million people worldwide annually. While many people experience mild symptoms resembling a common cold, the virus can cause serious complications in at-risk populations. Among U.S. adults aged 18 to 49 alone, RSV causes approximately 17,000 hospitalizations, 277,000 emergency department visits, and nearly 2 million outpatient medical visits each year.
People at highest risk include those with chronic conditions such as heart disease, lung disease (including COPD and asthma), kidney or renal disease, diabetes, and obesity. In these individuals, RSV can trigger severe illness, pneumonia, hospitalization, and even death—outcomes that are potentially preventable through vaccination.
How the Approval Was Determined
The FDA’s decision was based on robust clinical evidence from a phase IIIb trial involving 1,458 participants across six countries, including 16 U.S. sites. This trial demonstrated that the vaccine produces an immune response in adults aged 18–49 that is at least as strong as the response seen in adults aged 60 and older. Earlier phase III trials had already established the vaccine’s effectiveness in the older population. The safety profile remained consistent with previous studies, with most side effects being mild to moderate and temporary.
What to Expect
The most commonly reported side effects were mild and transient, including injection site pain, fatigue, muscle aches, headache, and joint pain, typically occurring within four days of vaccination. These reactions are consistent with how the body normally responds to vaccines as it builds immunity.
Broader Context
Arexvy has already been approved in 70 countries for adults aged 60 and older, and in more than 60 countries for adults aged 50–59 with increased risk. In the European Economic Area, the vaccine is already approved for all adults aged 18 and older, demonstrating the safety and efficacy data that supports this expanded use.
Moving Forward
GSK continues pursuing regulatory approvals across additional countries, working toward making RSV vaccination accessible to broader adult populations globally. This expansion represents meaningful progress in addressing a significant public health need and reducing the burden of RSV disease in vulnerable younger adults.
